Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Carrington Laboratories
Officials at Carrington Laboratories discuss recent developments
February 14th, 2007
Officials at Carrington Laboratories discuss recent developments. This trend article is an immediate alert from NewsRx to identify the most recent news developments at Carrington Laboratories. Report 1: Carrington Laboratories, Inc., (CARN) reported that GelVac, a dry powder nasal delivery formulation for vaccines, showed both antigen stabilization and high immunogenic effect in preclinical models. In addition, ongoing studies of GelVac formulations incorporating influenza antigens exhibited the potential for long-term stability during storage at room temperature. In a presentation entitled "A Stable Dry Powder...
Source: Medical Patent Law Weekly (2007-02-14)
|
